自身免疫性疾病、感染、抗生素使用与急性髓系白血病风险:一项全国性人群病例对照研究
该研究纳入丹麦2000至2013年诊断的3053例急性髓系白血病(AML)患者及30530名性别、年龄匹配的人群对照,采用条件logistic回归计算比值比。自身免疫性疾病与AML总体风险升高相关(OR 1.3,95%CI 1.1-1.5),但该风险仅见于既往有血液系统疾病或细胞毒治疗暴露者(继发性/治疗相关AML OR 2.0,95%CI 1.6-2.6),原发AML无显著关联(OR 1.1,95%CI 0.9-1.3)。因感染住院同样与AML风险升高相关(OR 1.3,95%CI 1.1-1.4),亦仅见于继发性/治疗相关AML(OR 1.8,95%CI 1.5-2.2),原发AML无显著关联(OR 1.1,95%CI 1.0-1.2)。
要点
- 自身免疫性疾病与AML总体风险升高相关(OR 1.3,95%CI 1.1-1.5),但仅见于继发性/治疗相关AML(OR 2.0,95%CI 1.6-2.6),原发AML无显著关联(OR 1.1,95%CI 0.9-1.3)。
- 因感染住院与AML风险升高相关(OR 1.3,95%CI 1.1-1.4),同样仅见于继发性/治疗相关AML(OR 1.8,95%CI 1.5-2.2),原发AML无显著关联(OR 1.1,95%CI 1.0-1.2)。
- 作者认为,炎症对原发AML的发生即使有作用也仅为次要作用。
核心结论
- 自身免疫性疾病和感染仅在有既往血液系统疾病和/或细胞毒治疗的受试者中与AML风险升高相关。
- 作者认为,炎症对原发AML的发生即使有作用也仅为次要作用。
研究设计与样本
- 全国性病例对照研究,纳入丹麦2000至2013年诊断的3053例AML患者和30530名性别、年龄匹配的人群对照。
- 检索自身免疫性疾病、感染和抗生素使用信息,采用条件logistic回归计算AML的比值比,并按AML类型、性别和年龄分层。
主要发现
- 自身免疫性疾病与AML总体风险升高相关(OR 1.3,95%CI 1.1-1.5)。
- 自身免疫性疾病相关风险仅见于既往有血液系统疾病或细胞毒治疗暴露者(继发性/治疗相关AML OR 2.0,95%CI 1.6-2.6),原发AML无显著关联(OR 1.1,95%CI 0.9-1.3)。
- 因感染住院与AML风险升高相关(OR 1.3,95%CI 1.1-1.4)。
- 感染相关风险仅见于继发性/治疗相关AML(OR 1.8,95%CI 1.5-2.2),原发AML无显著关联(OR 1.1,95%CI 1.0-1.2)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies reported increased risk of acute myeloid leukaemia (AML) in individuals with inflammatory conditions. However, it is unclear whether this association is explained by preceding cytotoxic therapy or haematological diseases. We conducted a nationwide case-control study that included 3053 AML patients, diagnosed in Denmark between 2000 and 2013, and 30 530 sex- and age-matched population controls. We retrieved information on autoimmune disease, infections, and use of antibiotics and computed odds ratios for AML (conditional logistic regression). Results were stratified by AML type, sex, and age. Autoimmune diseases were associated with an overall increased risk of AML {odds ratio [OR] 1·3 [95% confidence interval (CI) = 1·1-1·5]}. However, the risk was confined to patients with previous haematological disease or cytotoxic therapy exposure [secondary/therapy-related AML (sAML/tAML0) OR 2·0 (95% CI = 1·6-2·6)] and not de novo AML [OR 1·1 (95% CI = 0·9-1·3)]. Similarly, any prior infection requiring hospitalization was associated with a higher risk of AML [OR 1·3 (95% CI = 1·1-1·4)]. Again, this association was evident for sAML/tAML [OR 1·8 (95% CI = 1·5-2·2)], and not de novo AML [OR 1·1 (95% CI = 1·0-1·2)]. In conclusion, autoimmune diseases and infections were associated with an increased AML risk only in subjects with prior haematological disease and/or cytotoxic treatment. These observations suggest, that inflammation plays - if any - a minor role for the development of de novo AML.
引用
- Østgård LSG, Nørgaard M, Pedersen L, et al. Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. Br J Haematol. 2018. PMID: 29504124. doi:10.1111/bjh.15163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。